Detalhe da pesquisa
1.
Financial Relationships Between Pharmaceutical Companies and Rheumatologists in Japan Between 2016 and 2019.
J Clin Rheumatol
; 29(3): 118-125, 2023 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729793
2.
Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019.
Respiration
; 101(12): 1088-1098, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36353778
3.
Generic drug crisis in Japan and changes leading to the collapse of universal health insurance established in 1961: the case of Kobayashi Kako Co. Ltd.
Cost Eff Resour Alloc
; 21(1): 35, 2023 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37259132
4.
Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019.
Medicine (Baltimore)
; 102(4): e32776, 2023 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36705373
5.
Evaluation of Financial and Nonfinancial Conflicts of Interest and Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal Payments From Pharmaceutical Companies and Authors' Self-Citation Rate in Japan and the United States.
Arthritis Care Res (Hoboken)
; 75(6): 1278-1286, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36194077
6.
Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019.
Int J Environ Res Public Health
; 19(12)2022 06 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35742661
7.
Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan.
Clin Microbiol Infect
; 28(3): 460-462, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34826620